Land: Europäische Union
Sprache: Englisch
Quelle: EMA (European Medicines Agency)
dolutegravir sodium, lamivudine
ViiV Healthcare B.V.
J05AR
dolutegravir, lamivudine
Antivirals for systemic use
HIV Infections
Dovato is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and adolescents above 12 years of age weighing at least 40 kg, with no known or suspected resistance to the integrase inhibitor class, or lamivudine.
Revision: 14
Authorised
2022-06-10
48 B. PACKAGE LEAFLET 49 PACKAGE LEAFLET: INFORMATION FOR THE PATIENT DOVATO 50 MG/300 MG FILM-COATED TABLETS dolutegravir/lamivudine READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor, or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor, or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What Dovato is and what it is used for 2. What you need to know before you take Dovato 3. How to take Dovato 4. Possible side effects 5. How to store Dovato 6. Contents of the pack and other information 1. WHAT DOVATO IS AND WHAT IT IS USED FOR Dovato is a medicine that contains two active ingredients used to treat human immunodeficiency virus (HIV) infection: dolutegravir and lamivudine. Dolutegravir belongs to a group of anti-retroviral medicines called _integrase inhibitors _ (INIs), and lamivudine belongs to a group of anti-retroviral medicines called _nucleoside _ _analogue reverse transcriptase inhibitors _ (NRTIs). Dovato is used to treat HIV in adults and adolescents over 12 years old who weigh at least 40 kg. Dovato does not cure HIV infection; it keeps the amount of virus in your body at a low level. This helps maintain the number of CD4 cells in your blood. CD4 cells are a type of white blood cells that are important in helping your body to fight infection. Not everyone responds to treatment with Dovato in the same way. Your doctor will monitor the effectiveness of your treatment. 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE DOVATO _ _ DO NOT TAKE DOVATO • if you are ALLERGIC ( _hypersensitive_ ) to dolutegravir or lamivudine or any of the other ingredients of this medicine (listed in section 6). • If you are Lesen Sie das vollständige Dokument
1 ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 2 1. NAME OF THE MEDICINAL PRODUCT Dovato 50 mg/300 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains dolutegravir sodium equivalent to 50 mg dolutegravir and 300 mg lamivudine. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Film-coated tablet (tablet). Oval, biconvex, white, film coated tablet, approximately 18.5 x 9.5 mm, debossed with “SV 137” on one face. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Dovato is indicated for the treatment of Human Immunodeficiency Virus type 1 (HIV-1) infection in adults and adolescents above 12 years of age weighing at least 40 kg, with no known or suspected resistance to the integrase inhibitor class, or lamivudine (see section 5.1). 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Dovato should be prescribed by physicians experienced in the management of HIV infection. _ _ Posology _Adults and adolescents (above 12 years of age weighing at least 40_ _kg). _ _ _ The recommended dose of Dovato in adults and adolescents is one 50 mg/300 mg tablet once daily. _Dose adjustments _ A separate preparation of dolutegravir is available where a dose adjustment is indicated due to drug-drug interactions (e.g. rifampicin, carbamazepine, oxcarbazepine, phenytoin, phenobarbital, St. John’s wort, etravirine (without boosted protease inhibitors), efavirenz, nevirapine, or tipranavir/ritonavir, see sections 4.4 and 4.5). In these cases the physician should refer to the individual product information for dolutegravir. _Missed doses _ If the patient misses a dose of Dovato, the patient should take Dovato as soon as possible, providing the next dose is not due within 4 hours. If the next dose is due within 4 hours, the patient should not take the missed dose and simply resume the usual dosing schedule. _Elderly _ There are limited data available on the use of Dovato in patients aged 65 years and over. No dose adjustment is necessary (see section 5.2). _ _ 3 _Renal impair Lesen Sie das vollständige Dokument